You are here

  • Home
  • Archive
  • Volume 67, Issue 8
  • Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis

Article Text

Article menu
Download PDFPDF
Letter
Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis
  1. K Visser,
  2. K N Verpoort,
  3. H van Dongen,
  4. S M van der Kooij,
  5. C F Allaart,
  6. R E M Toes,
  7. T W J Huizinga,
  8. A H M van der Helm-van Mil
  1. Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  1. Miss K Visser, Leiden University Medical Centre, Department of Rheumatology, PO Box 9600, 2300 RC Leiden, The Netherlands; K.Visser{at}lumc.nl

https://doi.org/10.1136/ard.2008.088070

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To direct individual treatment decisions in recent-onset rheumatoid arthritis (RA), predictors of treatment response to methotrexate (MTX) need to be identified. Disease activity at baseline, gender and genetic polymorphisms have already been found to be associated with the effect of MTX treatment, but the predictive value of autoimmune antibody status remains less clear.1 2 It has been shown, however, that both the presence and level of anti-cyclic citrullinated peptide antibodies (ACPA) are strongly associated with a worse disease course.3 Therefore, we investigated the potential predictive effect of levels of ACPA in ACPA-positive patients for the response to MTX treatment. As observations from our cohort and others indicate that ACPA levels decrease …

    View Full Text

    Footnotes

    • Funding: The PROMPT study was financed with grants from the Dutch Arthritis Foundation and the Netherlands Organisation for Scientific Research. The BeSt study was financed with grants from the Dutch College of Health Insurances, Schering-Plough BV and Centocor Inc.

    • Competing interests: None.

    • Ethics approval: Ethics committee approval obtained.